Drug intelligence / Profile preview

EDI-M418

Development stage: Preclinical
Lead developer: Empire Discovery Institute
Modality: Small Molecules
Administration: Oral

Overview

EDI-M418 is a preclinical-stage small molecule allosteric inhibitor of mutant epidermal growth factor receptor (EGFR), developed by the Empire Discovery Institute. It is specifically designed to treat non-small cell lung cancer (NSCLC) by targeting mutant forms of EGFR that are resistant to standard-of-care orthosteric tyrosine kinase inhibitors (TKIs). By binding to an allosteric site, EDI-M418 aims to inhibit EGFR signaling even in the presence of common resistance mutations like T790M and C797S, potentially offering a new therapeutic avenue for patients with advanced NSCLC.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on EDI-M418.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDI-M418.

Explore the full profile